⌘K

Login Start Free

Home/Filings/4/0000950170-25-075148

4//SEC Filing

Bolte Axel 4

Accession 0000950170-25-075148

CIK 0001693011other

View on SEC.gov Company Profile

Filed

May 19, 8:00 PM ET

Accepted

May 20, 4:00 PM ET

Size

10.0 KB

Accession

0000950170-25-075148

Insider Transaction Report

Form 4

Period: 2025-05-15

Inozyme Pharma, Inc.INZY

Director

Transactions

Exercise/Conversion
Common Stock
2025-05-15$0.98/sh+152,823$149,767→ 419,519 total
Exercise/Conversion
Common Stock
2025-05-15$0.98/sh+4,407$4,319→ 423,926 total
Exercise/Conversion
Stock Option (right to buy)
2025-05-15−152,823→ 0 total
Exercise: $0.98Exp: 2027-06-27→ Common Stock (152,823 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-05-15−4,407→ 0 total
Exercise: $0.98Exp: 2027-06-27→ Common Stock (4,407 underlying)

Footnotes (1)

[F1]These options are fully vested.

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Inozyme Pharma, Inc.

CIK 0001693011

Entity typeother

Related Parties

1

filerCIK 0001579247

Filing Metadata

Form type: 4
Filed: May 19, 8:00 PM ET
Accepted: May 20, 4:00 PM ET
Size: 10.0 KB

View on SEC.gov